Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

2 of 0 completed with results

Key Signals

2 with results

Data Visualizations

Phase Distribution

1Total
P 2 (1)

Trial Status

Unknown3

Clinical Trials (3)

Showing 3 of 3 trials
NCT04913597UnknownPrimary

A Study of Switching Avatrombopag and Rh-TPO in ITP

NCT04214951UnknownPrimary

A Study of Eltrombopag and Recombinant Human Thrombopoietin In Primary Immune Thrombocytopenia

NCT03909763Phase 2UnknownPrimary

Combination of Danazole With Berberine in the Treatment of ITP

Showing all 3 trials

Research Network

Activity Timeline